ADAM17 Polyclonal Antibody

Product Specifications

Background

Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT) . Plays a role in the proteolytic processing of ACE2.

Synonyms

CSVP; TACE; NISBD; ADAM18; CD156B; NISBD1; Disintegrin and metalloproteinase domain-containing protein 17; ADAM 17; Snake venom-like protease; TNF-alpha convertase; TNF-alpha-converting enzyme; ADAM17

Gene ID

6868

Swiss Prot

P78536

Cellular Locus

Cell membrane

Host

Rabbit

Cross Reactivity

Human, Mouse, Rat

Immunogen

201-300/824

Target

ADAM17

Clonality

Polyclonal

Isotype

IgG

Conjugation

Unconjugated

Source

KLH conjugated synthetic peptide derived from human ADAM17

Applications

WB, ELISA, FCM, IHC-P, IHC-F, IF (IHC-P), IF (IHC-F), IF (ICC)

Purification

Purified by Protein A.

Concentration

1µg/µl

Dilution

WB (1:300-5000), ELISA (1:500-1000), FCM (1:20-100), IHC-P (1:200-400), IHC-F (1:100-500), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)